Chlorophyllin for Health & Longevity

Evidence Review created on 10/19/2026 using AI4L + evidence-mcp / Gemini 4 Argon

Also known as: Sodium Copper Chlorophyllin, Copper Chlorophyllin, Chlorophyllin Copper Complex, Potassium Sodium Copper Chlorophyllin, Sodium Magnesium Chlorophyllin, Sodium Iron Chlorophyllin, Trisodium Copper Chlorin e6, Disodium Copper Chlorin e4, Derifil, Nullo, Chloresium, Shengxuening, Yebaike, E141

Motivation

Chlorophyllin (most commonly formulated as sodium copper chlorophyllin) is a water-soluble derivative of natural plant chlorophyll in which the central magnesium atom is replaced with a more stable metal ion and the fat-soluble tail is removed. Unlike natural chlorophyll in leafy greens, which breaks down rapidly during digestion and heat exposure, oral chlorophyllin remains intact throughout the digestive tract. Health-oriented adults have increasingly turned to it as a daily oral supplement to bind dietary toxins in the gut and support cellular defense against everyday chemical exposures.

Originally introduced in mid-twentieth-century medicine for wound care and internal odor control, chlorophyllin later drew scientific attention from cancer-prevention researchers studying populations exposed to mold-contaminated grains and charred meats. Human trials have investigated whether administering oral chlorophyllin alongside meals alters the absorption of foodborne toxins, controls body and urinary odors, or influences white blood cell counts, while laboratory experiments have explored its effects on cellular stress responses and animal lifespan.

This review examines the human clinical trials, laboratory evidence, safety profile, and practical dosing protocols for chlorophyllin to clarify what the evidence shows for health and longevity.

Benefits - Risks - Protocol - Conclusion

This section curates five accessible expert overviews, narrative reviews, and foundational clinical studies covering the chemistry, mechanisms, and human applications of chlorophyllin.

Searches of the other prioritized expert platforms — Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman (Huberman Lab), Chris Kresser, and Lifespan.io — found no dedicated articles or episodes on chlorophyllin; where natural chlorophyll is mentioned on FoundMyFitness, Huberman Lab, or Chris Kresser’s site, coverage is limited to dietary leafy greens and magnesium or heme-iron binding rather than supplemental chlorophyllin.

Grokipedia

Chlorophyllin

Overview of semi-synthetic sodium copper chlorophyllin covering its chemical synthesis from plant chlorophyll, regulatory status as a food and cosmetic colorant, and human evidence for aflatoxin binding, odor control, and topical wound care.

Examine

Chlorophyll

Examine’s dedicated page covers water-soluble sodium copper chlorophyllin alongside plant chlorophyll, evaluating human evidence for aflatoxin binding, trimethylaminuria (fish-odor syndrome, a metabolic disorder causing fishy body odor) control, skin care, and 100–300 mg daily dosing.

ConsumerLab

Chlorophyll & Chlorophyllin: Health Benefits and Safety

Explains why dietary supplements typically use semi-synthetic water-soluble chlorophyllin rather than natural plant chlorophyll, details how sodium copper chlorophyllin and sodium magnesium chlorophyllin appear on labels, and outlines cancer-prevention, deodorant, and sun-sensitivity evidence.

Systematic Reviews

This section lists the published systematic reviews and meta-analyses indexed on PubMed that evaluate clinical formulations of chlorophyllin.

No systematic review or meta-analysis on PubMed evaluates oral sodium copper chlorophyllin for carcinogen trapping, internal deodorization, or longevity, nor does any systematic review assess its principal risks of cutaneous photosensitivity (light-induced skin reactions), false-positive fecal occult blood tests, or copper accumulation.

Mechanism of Action

Chlorophyllin acts primarily as a molecular “interceptor” in the gastrointestinal lumen and secondarily as a systemic modulator of cellular stress pathways. Its flat porphyrin ring forms non-covalent pi-pi complexes with planar aromatic compounds—including aflatoxin B1, polycyclic aromatic hydrocarbons, and heterocyclic amines from charred meat—reducing intestinal uptake and promoting fecal elimination (Egner et al., 2001; Jubert et al., 2009). Intraluminally, it also sequesters volatile amines and downregulates inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ, an enzyme triggering inflammatory signaling) and nuclear factor kappa B (NF-κB, a protein complex activating inflammatory genes) (Zheng et al., 2018).

Systemically absorbed chlorin metabolites activate phosphoinositide 3-kinase (PI3K, an intracellular survival-signaling enzyme) and protein kinase B (AKT, a signaling enzyme downstream of PI3K), triggering nuclear factor erythroid 2-related factor 2 (NRF2, a transcription factor activating antioxidant genes) to upregulate heme oxygenase-1 (HO-1, an enzyme degrading pro-oxidant heme) and NAD(P)H quinone dehydrogenase 1 (NQO1, a quinone-detoxifying enzyme) (Zhang et al., 2008). Competing hypotheses attribute chemoprevention primarily to gut trapping versus systemic NRF2 activation and non-specific inhibition of cytochrome P450 (CYP, drug- and procarcinogen-metabolizing enzymes including CYP1A1, CYP1A2, and CYP3A4) (Yun et al., 1995). Saponification yields water-soluble trisodium copper chlorin e6 and disodium copper chlorin e4 with a rodent elimination half-life (t1/2, time for blood concentration to halve) of ~2.3 hours (Indian Patent 557545 holders; Ramani et al., 2025), human steady-state serum accumulation (Egner et al., 2000), and hepatic, renal, and fecal distribution with intact copper chelation (Viera et al., 2025).

Historical Context & Evolution

Water-soluble chlorophyll derivatives entered medicine in the 1940s and 1950s as topical ointments (Chloresium) for wounds, burns, and ulcers, where clinicians reported faster healing and reduced odor (Bowers, 1947; Smith, 1955). Topical deodorization prompted oral dosing (100–300 mg/day as Derifil and Nullo) for ostomy and incontinence odors (Siegel, 1960; Young & Beregi, 1980). In 1990, the United States Food and Drug Administration (FDA, federal agency regulating food, drugs, and supplements) established an over-the-counter (OTC, non-prescription) monograph recognizing oral chlorophyllin copper complex as generally recognized as safe and effective (GRASE, federal standard for OTC drug approval) for internal deodorization (Code of Federal Regulations Title 21 Part 357 Subpart I), though small crossover trials found odor reductions matched placebo (Nahata et al., 1983; Christiansen et al., 1989).

Focus shifted toward prevention in the 1980s and 1990s when Dashwood, Bailey, and Kensler showed that chlorophyllin complexes with dietary mutagens. This led to the 2001 Qidong RCT showing a 55% reduction in urinary aflatoxin-DNA adducts (Egner et al., 2001) and a 2009 human microdosing study confirming lower carcinogen uptake (Jubert et al., 2009). Concurrently, clinical trials in China evaluated oral sodium copper chlorophyllin (Yebaike) for leukopenia (low white blood cell count) (Gao & Hu, 2005) and sodium iron chlorophyllin (Shengxuening) for anemia (Zheng et al., 2025), while oncology groups in India launched phase I–III trials for radiation injury and immune modulation (Dasgupta et al., 2025; Prakash et al., 2026; Indian Patent 557545 holders: Patwardhan et al., 2026).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: human trials of oral sodium copper chlorophyllin for carcinogen binding and leukocyte recovery come from single research groups without independent replication on clinical endpoints, while randomized trials for internal deodorization are conflicted and multi-trial anemia meta-analyses evaluate only the prescription iron-chelated derivative sodium iron chlorophyllin.

Medium 🟩 🟩

Reduced Dietary Carcinogen Absorption and DNA Adduct Formation

Mealtime oral sodium copper chlorophyllin traps planar foodborne carcinogens such as aflatoxin B1 in the gut, reducing systemic uptake and hepatic DNA adducts. A 4-month RCT in 180 high-risk adults (100 mg three times daily; Egner et al., 2001) reduced urinary aflatoxin-N7-guanine adducts, and a crossover study (150 mg; Jubert et al., 2009) lowered plasma maximum concentration (Cmax, peak blood level) and area under the concentration-time curve (AUC, total exposure over time). Evidence comes from one research network and tracks biomarkers rather than cancer incidence.

Magnitude: 55% lower median urinary aflatoxin-N7-guanine DNA adduct levels than placebo (P = 0.036; 95% confidence interval [CI, the range within which the true effect is likely to fall] and absolute group medians not reported) in a 180-adult RCT (Egner et al., 2001).

White Blood Cell Recovery in Leukopenia ⭕️ Not Central to Health & Longevity

Bears on clinical management of leukopenia rather than general longevity optimization. Oral sodium copper chlorophyllin stimulates myeloid differentiation and peripheral leukocyte recovery. In a 1-month RCT of 105 leukopenia patients comparing oral sodium copper chlorophyllin (Yebaike, 40 mg three times daily, n = 60), Leucogen (20 mg three times daily, n = 30), and vitamin C placebo (100 mg three times daily, n = 15), Gao & Hu, 2005 found superior recovery versus placebo and equivalence to Leucogen. Independent replication is lacking.

Magnitude: 85.0% (51/60) total effective rate with oral sodium copper chlorophyllin versus 26.7% (4/15) with placebo (P < 0.01; 95% CI not reported) in a 105-patient RCT (Gao & Hu, 2005).

Low 🟩

Internal Deodorization in Trimethylaminuria and Incontinence ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Bears on odor control rather than longevity. Copper chlorophyllin (180 mg/day) lowered urinary trimethylamine (TMA, a fishy-smelling metabolite) in trimethylaminuria (fish-odor syndrome) (Yamazaki et al., 2004), whereas incontinence and colostomy RCTs matched placebo (Nahata et al., 1983; Christiansen et al., 1989). Evidence supports TMA binding but no general odor effect.

Magnitude: No statistically significant difference versus placebo in a 20-patient urinary odor crossover RCT (21% visual analog scale [VAS, a standardized symptom rating line] reduction on chlorophyllin versus 9% increase on placebo; Nahata et al., 1983) or a 28-patient colostomy RCT (Christiansen et al., 1989); normalized trimethylamine N-oxide (TMAO, the odorless oxidized metabolite of TMA) capacity from 70%–90% to >90% in 7 trimethylaminuria patients (no control group; Yamazaki et al., 2004).

Iron Deficiency and Renal Anemia Correction ⭕️ Not Central to Health & Longevity

Bears on clinical anemia treatment rather than longevity. Graded Low as indirect evidence because all trials tested the prescription iron-chelated analogue sodium iron chlorophyllin (Shengxuening), which supplies porphyrin iron, rather than standard copper chlorophyllin (Zheng et al., 2025; Zhang et al., 2022; Li et al., 2022; Zeng et al., 2020).

Magnitude: Hemoglobin mean difference (MD, average numerical difference between groups) of 7.15 g/L above placebo (95% CI 5.68 to 8.62 g/L), ferritin MD of 57.53 ng/mL above placebo (95% CI 29.70 to 85.36 ng/mL), and transferrin saturation (TSAT, percentage of iron-binding sites occupied) MD of 7.00% above placebo (95% CI 3.40% to 10.60%) across 31 RCTs (N = 2,372) of sodium iron chlorophyllin (Zheng et al., 2025), plus standardized mean difference (SMD, effect size relative to variability) of 1.11 for hemoglobin (95% CI 0.75 to 1.46) and relative risk (RR, ratio of outcome probabilities) of 1.06 for total effective rate (95% CI 1.02 to 1.09) across 39 trials (Zhang et al., 2022).

Colorectal DNA Damage Reduction from Cooked Meat Mutagens

In a 4-week crossover trial of 16 adults eating high-temperature (250°C) fried meat, oral chlorophyllin tablets lowered colorectal cell DNA damage and fecal mutagenicity (Shaughnessy et al., 2011). Graded Low as indirect evidence because chlorophyllin was co-administered with cruciferous vegetables and yogurt, preventing isolation of its sole effect.

Magnitude: Target colorectal cell DNA damage decreased nearly twofold (~50% lower than the uninhibited fried-meat diet, P < 0.05; 95% CI not reported) with the combined chlorophyllin, cruciferous vegetable, and yogurt regimen (Shaughnessy et al., 2011).

Topical Skin Photodamage, Acne, and Wound Care ⭕️ Not Central to Health & Longevity

Bears on dermatology and wound care rather than longevity. Graded Low for topical route in small pilot studies funded and co-authored by MDRejuvena, Inc. and Discovery Partners LLC (Sigler & Stephens, 2015; Stephens et al., 2015; McCook et al., 2016) and combination papain-urea-chlorophyllin debriding ointments (Ramundo & Gray, 2008).

Magnitude: Statistically significant within-group clinical score improvements in photodamage and acne over 3–8 weeks in 10-subject open-label topical studies (no control group; exact score deltas not reported in abstracts) (Sigler & Stephens, 2015; Stephens et al., 2015).

Radiation-Induced Hemorrhagic Cystitis Relief ⭕️ Not Central to Health & Longevity

Bears on oncology care rather than longevity. Following mouse bladder-protection data (Ramani et al., 2025), the 24-patient single-arm phase II CLARITY trial in radiation hemorrhagic cystitis (bladder inflammation with bleeding) found oral chlorophyllin (750 mg/day) resolved hematuria (blood in urine) (Prakash et al., 2026), though RCTs are lacking.

Magnitude: 70.8% (17/24; 95% CI 65% to 83%) overall objective response rate and 62.5% (15/24) complete hematuria resolution at 3 months in a 24-patient single-arm phase II trial (no control group; Prakash et al., 2026).

Speculative 🟨

Lifespan Extension

Chlorophyllin extended female Drosophila melanogaster lifespan and radiation survival (Cruces et al., 2022), while chlorophyll extended Caenorhabditis elegans lifespan via forkhead box O (DAF-16/FOXO, longevity regulator; Wang & Wink, 2016). Human lifespan is unstudied.

Gut Barrier Protection and Hepatic Fibrosis Attenuation

In mice, oral chlorophyllin restored intestinal tight-junction proteins, reduced colonic inflammation, and attenuated carbon tetrachloride-induced liver fibrosis by inhibiting IKKβ/NF-κB signaling (Zheng et al., 2018; Zhang et al., 2022). Evidence is entirely preclinical.

Antiviral Activity and Immune Modulation

Chlorophyllin blocked enterovirus A71 cell entry (Liu et al., 2020) and inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while modulating lymphocytes (Indian Patent 557545 holders; Patwardhan et al., 2026). Clinical efficacy remains unproven.

Calcium Oxalate Kidney Stone Inhibition ⭕️ Not Central to Health & Longevity

Bears on kidney stone prevention rather than longevity. Soluble sodium copper chlorophyllin inhibits calcium oxalate crystal growth in rat urine and in vitro (Tawashi et al., 1980; Tawashi et al., 1982). No human trials exist.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in flavin-containing monooxygenase 3 (FMO3, liver enzyme oxidizing TMA to TMAO) drive trimethylaminuria response (Yamazaki & Shimizu, 2007), while null glutathione S-transferase (GSTM1, GSTT1, carcinogen-conjugating enzymes) and epoxide hydrolase 1 (EPHX1, epoxide-detoxifying enzyme) variants raise aflatoxin-adduct risk.
  • Baseline toxin and biomarker levels: Benefits depend on baseline exposure; individuals consuming mold-contaminated grains, charred meats, or exhibiting elevated urinary TMA or leukopenia experience measurable biomarker improvements that low-exposure adults do not (Egner et al., 2001; Shaughnessy et al., 2011).
  • Sex-based differences: In Drosophila melanogaster, dietary sodium copper chlorophyllin extended lifespan in females but not males (Cruces et al., 2022), whereas human carcinogen-binding and leukopenia trials showed comparable responses across sexes (Egner et al., 2001; Gao & Hu, 2005).
  • Pre-existing health conditions: Chronic hepatitis B infection, impaired hepatic detoxification, secondary leukopenia, and genetic trimethylaminuria amplify the absolute benefit of carcinogen trapping, hematologic support, or intraluminal amine sequestration (Egner et al., 2001; Yamazaki et al., 2004).
  • Age-related considerations: Older adults with slower gastrointestinal transit or age-related declines in hepatic phase II conjugation may derive greater intraluminal mutagen-binding and stool-regulating benefit (Young & Beregi, 1980), though age-stratified longevity trials in humans have not been conducted.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: randomized controlled trials of oral sodium copper chlorophyllin report no statistically significant excess of clinical adverse events over placebo, and documented harms derive from regulatory labeling, open-label surveillance, case series, or preclinical models.

Medium 🟥 🟥

No risk reaches Medium: controlled trials of oral sodium copper chlorophyllin found zero clinical adverse events versus placebo, and meta-analyses of the iron-chelated derivative found lower gastrointestinal adverse-event rates than standard oral iron salts.

Low 🟥

Mild Gastrointestinal Distress (Diarrhea, Cramps, and Nausea) ⚠️ Conflicted

Oral chlorophyllin can cause loose stools, cramps, or nausea (21 CFR § 357.850; Chlorophyllin Side Effects; Ding et al., 2019, Wuhan United Pharmaceutical). Yet RCTs reported zero events (Egner et al., 2001) and meta-analyses showed fewer events than comparators (Zheng et al., 2025). Mild laxative effects do not exceed placebo.

Magnitude: 0% adverse events in both chlorophyllin (0/90) and placebo (0/90) groups at 300 mg/day in a 4-month RCT (Egner et al., 2001); lower adverse drug reactions with sodium iron chlorophyllin than comparator drugs (odds ratio [OR, ratio of event odds between groups] 0.20, 95% CI 0.12 to 0.33; Zheng et al., 2025) and RR 0.24 (95% CI 0.18 to 0.31; Zhang et al., 2022); 2.83% nausea and 0.74% diarrhea in open-label surveillance (no control group; Ding et al., 2019) and 16% nausea at 750 mg/day in a 24-patient single-arm trial (no control group; Prakash et al., 2026).

Harmless Green Discoloration of Stool, Urine, Saliva, and Serum

Unabsorbed chlorophyllin pigments turn stool dark green, while absorbed copper chlorin e4 and copper chlorin e4 ethyl ester tint blood plasma and occasionally urine green (Egner et al., 2000; Young & Beregi, 1980; Chlorophyllin Side Effects). The effect is benign and reverses after cessation.

Magnitude: Green discoloration and quantifiable copper chlorin e4 ethyl ester detected in 100% of sampled chlorophyllin-group sera versus 0% of placebo-group sera in the Qidong RCT (Egner et al., 2000), and green stool discoloration reported in 79% of patients receiving 750 mg/day in a 24-patient single-arm trial (no control group; Prakash et al., 2026).

False-Positive Guaiac Fecal Occult Blood Tests

Chlorophyllin’s tetrapyrrole ring exhibits pseudoperoxidase activity that oxidizes guaiac reagent on standard guaiac fecal occult blood test (gFOBT, a peroxidase-based stool blood screen) cards (Gogel et al., 1989; Young & Beregi, 1980). This produces false-positive readings that can prompt unnecessary diagnostic endoscopy.

Magnitude: Not quantified in available studies. No controlled clinical trial has measured false-positive screening rates in supplemented versus control cohorts, with evidence derived from laboratory guaiac reactivity evaluations (Gogel et al., 1989).

Cutaneous Photosensitivity and Pseudoporphyria

Circulating porphyrin and pheophorbide metabolites can accumulate in skin and generate singlet oxygen under sunlight, causing pseudoporphyria (a blistering, fragile-skin disorder mimicking porphyria cutanea tarda without abnormal endogenous porphyrins) (Rossi et al., 2015; Zhao et al., 2016). Lesions heal slowly over months after stopping use.

Magnitude: Not quantified in available studies. No controlled trial or cohort study has measured incidence, with human data limited to 6 patients across two dermatology case series (Rossi et al., 2015; Zhao et al., 2016).

Local Irritation and Hypersensitivity from Topical Formulations

Topical chlorophyllin ointments occasionally cause transient local burning, itching, or skin redness (Smith, 1955). Prescription papain-urea-chlorophyllin debriding ointments were associated with anaphylaxis (severe allergic shock) attributed to the papain enzyme (Ramundo & Gray, 2008; Chlorophyllin Side Effects). Graded Low for topical route and combination confounding.

Magnitude: Not quantified in available studies. Historical clinical reviews and wound series did not compare isolated topical chlorophyllin irritation rates against a vehicle control group (Smith, 1955).

Speculative 🟨

Context-Dependent Colon Tumor Promotion

In rats injected with 1,2-dimethylhydrazine, adding 1.5 mM sodium copper chlorophyllin to drinking water raised colon tumor incidence from 10% to 47% (Nelson, 1992). No tumor promotion has been observed in humans.

Systemic Copper Accumulation

Sodium copper chlorophyllin contains ~4%–5% copper by weight, and mouse studies show copper remains chelated to chlorin metabolites in serum and liver (Viera et al., 2025). Human copper toxicity remains undocumented.

Risk-Modifying Factors

  • Genetic polymorphisms: Loss-of-function mutations in ATPase copper transporting beta (ATP7B, the hepatic copper-exporting transporter mutated in Wilson disease) or UDP-glucuronosyltransferase 1A1 (UGT1A1, the enzyme conjugating bilirubin and porphyrins) impair biliary clearance of copper and porphyrin metabolites.
  • Baseline biomarker levels: Elevated baseline serum copper, low ceruloplasmin, or elevated liver transaminases increase susceptibility to copper accumulation or impaired hepatobiliary clearance of absorbed copper chlorin e4 derivatives (Egner et al., 2000; Viera et al., 2025).
  • Sex-based differences: Published dermatological case series of chlorophyll-associated pseudoporphyria and clinical trials of oral chlorophyllin do not establish a consistent sex-based difference in adverse-event rates (Rossi et al., 2015; Zhao et al., 2016).
  • Pre-existing health conditions: Cholestasis (impaired bile flow), biliary obstruction, cutaneous porphyrias, chronic diarrheal disorders, and severe ultraviolet sensitivity heighten the risks of porphyrin retention, photosensitivity, or loose stools (Rossi et al., 2015; 21 CFR § 357.850).
  • Age-related considerations: Older adults undergoing colorectal screening face a higher risk of false-positive gFOBT results if chlorophyllin is not paused beforehand, and age-related skin thinning may worsen pseudoporphyria blistering (Gogel et al., 1989; Rossi et al., 2015).

Key Interactions & Contraindications

  • Photosensitizing prescription drugs (doxycycline, voriconazole, hydrochlorothiazide, amiodarone): Caution (theoretical); co-administration may produce additive ultraviolet-A skin phototoxicity and pseudoporphyria blistering (Rossi et al., 2015; Zhao et al., 2016). Sun protection and stopping use if skin fragility develops reduce risk.
  • Planar aromatic drugs and CYP substrates (doxorubicin, irinotecan, tacrolimus, warfarin): Caution (theoretical); chlorophyllin binds aromatic rings (Pietrzak et al., 2003) and inhibits human liver microsomal CYP1A1, CYP1A2, and CYP3A4 (Yun et al., 1995). Staggered oral dosing (2–3 hours) limits interaction.
  • Over-the-counter oral drugs and laxatives (ibuprofen, naproxen, loperamide, magnesium hydroxide): Caution (theoretical); gut binding may lower absorption of aromatic nonsteroidal anti-inflammatory drugs (NSAIDs, cyclooxygenase-inhibiting pain relievers), while laxatives compound loose stools (21 CFR § 357.850). Two-hour spacing limits binding.
  • Copper, zinc, and polyphenol supplements (copper gluconate, zinc picolinate, green tea catechins): Monitor (theoretical); sodium copper chlorophyllin adds ~4–12 mg copper/day (Viera et al., 2025), and tea polyphenols may alter uptake (NCT04849832). Omitting extra copper and staggering tea limits overlap.
  • Photosensitizing herbal supplements (St. John’s wort [Hypericum perforatum], dong quai [Angelica sinensis]): Caution (theoretical); hypericin and furanocoumarins generate singlet oxygen under sunlight, compounding chlorophyllin-induced dermal photosensitivity (Rossi et al., 2015). Avoiding concurrent use during high ultraviolet exposure reduces risk.
  • Diagnostic stool tests and phototherapy (gFOBT, ultraviolet-A phototherapy): Caution; chlorophyllin causes false-positive gFOBT readings (Gogel et al., 1989) and increases phototoxicity during light therapy. A 5–7 day pause or antibody-based fecal immunochemical test (FIT, human-hemoglobin-specific stool test) avoids interference.

Populations who should avoid Chlorophyllin:

  • Individuals with Wilson disease or biliary copper-excretion disorders (specifically regarding sodium copper chlorophyllin formulations, whereas copper-free sodium magnesium chlorophyllin lacks copper).
  • Individuals with cutaneous porphyrias, pseudoporphyria, or severe photosensitivity disorders (Rossi et al., 2015; Zhao et al., 2016).
  • Pregnant and lactating women (no controlled human safety trials exist for oral sodium copper chlorophyllin during pregnancy or lactation; Chlorophyll and Metallo-Chlorophyll Derivatives).
  • Children under 12 years of age without physician supervision (21 CFR § 357.850 sets the OTC oral monograph threshold at age 12 years and older).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Gradual dose titration: Starting at 100 mg/day orally without exceeding the FDA OTC maximum of 300 mg/day (21 CFR § 357.850), and reducing the dose if cramps or diarrhea occur, prevents gastrointestinal distress.
  • Pre-screening pause or FIT substitution: Discontinuing oral chlorophyllin 5–7 days before collecting stool samples for gFOBT, or using an antibody-based FIT instead, prevents false-positive occult blood readings (Gogel et al., 1989).
  • Sodium magnesium chlorophyllin or copper tracking: Using copper-free sodium magnesium chlorophyllin, or checking serum copper every 6–12 months and stopping if levels exceed the 140 μg/dL reference limit (common practice), prevents systemic copper-chlorin retention (Viera et al., 2025).
  • Broad-spectrum photoprotection: Daily broad-spectrum sunscreen (sun protection factor ≥30) and immediate cessation if hand blistering, skin fragility, or redness appears prevents persistent pseudoporphyria (Rossi et al., 2015; Zhao et al., 2016).
  • Staggered medication timing: Taking oral chlorophyllin with meals while separating it by 2–3 hours from narrow-therapeutic-index oral prescription drugs prevents intraluminal complexation or CYP enzyme interference (Pietrzak et al., 2003; Yun et al., 1995).

Therapeutic Protocol

Other parameters without a citation (such as meal-matching schedules, cycling, and titration steps) reflect common practice.

  • Standard chemopreventive protocol: 100 mg oral sodium copper chlorophyllin three times daily with meals (300 mg/day), popularized by the Linus Pauling Institute, Johns Hopkins (Egner et al., 2001; Chlorophyll and Metallo-Chlorophyll Derivatives), and Life Extension (Chlorophyllin Protects Against Environmental Toxins).
  • Alternative regimens: 100–300 mg/day for odor (21 CFR § 357.850); 180 mg/day for trimethylaminuria (Yamazaki et al., 2004); 120 mg/day for leukopenia (Gao & Hu, 2005); and 500–750 mg/day for radioprotection (NCT07837713; Dasgupta et al., 2025).
  • Best time of day: Taken immediately before or at the start of meals containing potential dietary mutagens (such as grilled meats, grains, or nuts) so chlorophyllin mixes with food in the stomach (Egner et al., 2001; Jubert et al., 2009).
  • Half-life and split dosing: Formal human elimination half-life is unestablished (rodent half-life is ~2.3 hours; Ramani et al., 2025), and because carcinogen trapping requires gut presence during digestion, split mealtime dosing is preferred over single daily dosing.
  • Genetic polymorphisms: FMO3 variant carriers with trimethylaminuria use 60 mg three times daily (Yamazaki et al., 2004), GSTM1/GSTT1 null carriers prioritize mealtime dosing, and ATP7B carriers use copper-free sodium magnesium chlorophyllin.
  • Sex-based protocol considerations: Human clinical trials use identical oral dosing in men and women without sex-based dose adjustments (Egner et al., 2001; Gao & Hu, 2005).
  • Age-related protocol considerations: Older adults typically initiate oral dosing at 100 mg once daily with their largest meal and titrate over 1–2 weeks to 100 mg two or three times daily to confirm bowel tolerance (Young & Beregi, 1980).
  • Baseline biomarker considerations: Baseline serum copper, ceruloplasmin, and liver enzyme testing precedes chronic daily sodium copper chlorophyllin; when serum copper is near the upper reference limit, a single 100 mg targeted-meal dose or copper-free sodium magnesium chlorophyllin is used.
  • Pre-existing health condition adjustments: Individuals with diarrhea-predominant irritable bowel syndrome typically start at 50–100 mg/day, whereas clinical protocols for iron deficiency anemia use the iron-chelated form (sodium iron chlorophyllin) rather than copper chlorophyllin (Zheng et al., 2025).

Discontinuation & Cycling

  • Lifelong versus episodic use: Chlorophyllin can be used episodically alongside high-mutagen meals (such as charred meats) or in 3-week to 4-month courses (Egner et al., 2001; Yamazaki et al., 2004), rather than requiring continuous lifelong daily administration in low-exposure settings.
  • Withdrawal effects: No physiological dependence, rebound hypersecretion, or withdrawal syndrome occurs when stopping oral or topical chlorophyllin; green discoloration of stool and serum resolves within several days of cessation (Egner et al., 2000).
  • Tapering-off protocol: No tapering is required; supplementation can be stopped abruptly at any time, including an immediate 5–7 day pause prior to guaiac fecal occult blood screening (Gogel et al., 1989).
  • Cycling for efficacy: Gut toxin trapping does not desensitize, but cycling (8–12 weeks on, 2–4 weeks off) limits cumulative copper intake; in trimethylaminuria, odor control lasted weeks after a 3-week course (Yamazaki et al., 2004).

Sourcing and Quality

  • Chemical form and label verification: Many supplements labeled “chlorophyll” actually contain semi-synthetic sodium copper chlorophyllin (Chlorophyll & Chlorophyllin: Health Benefits and Safety). The Supplement Facts panel specifies “sodium copper chlorophyllin” (~4–4.5 mg copper/100 mg) or copper-free “sodium magnesium chlorophyllin.”
  • Compositional purity and chlorin ratios: Commercial sodium copper chlorophyllin is a mixture of trisodium copper chlorin e6, disodium copper chlorin e4, and copper chlorin e4 ethyl ester, and variable saponification alters mutagen-binding potency across batches (Dashwood, 1997).
  • Heavy metal testing: Extracted from alfalfa (Medicago sativa), mulberry leaves (Morus alba), or silkworm excreta, raw material can accumulate soil lead or arsenic; certification by United States Pharmacopeia (USP, pharmacopeial standards body) or NSF International (NSF, independent certifier) verifies purity.
  • Solid capsules versus liquid drops: Capsules and coated tablets delivering 100 mg per unit avoid severe staining of teeth, oral mucosa, and clothing caused by concentrated liquid chlorophyllin drops and protect against photodegradation when stored in opaque containers.
  • Established brands: Widely used oral sodium copper chlorophyllin capsules (100 mg per softgel or capsule) include Life Extension Chlorophyllin, NOW Foods Chlorophyll (containing sodium copper chlorophyllin), and Nature’s Way Chlorofresh.

Practical Considerations

Interaction with Foundational Habits

  • Sleep: None; chlorophyllin has no central nervous system stimulant or sedative activity and does not directly alter sleep architecture, though taking the final daily dose with an early evening meal avoids nocturnal gastrointestinal motility or mild cramping in sensitive individuals.
  • Nutrition: Direct potentiating interaction; mealtime dosing with charred meat, moldy grain, or choline-rich food traps mutagens and TMA (Egner et al., 2001; Yamazaki et al., 2004). Cruciferous vegetables and yogurt aided DNA protection (Shaughnessy et al., 2011); tea may alter uptake (NCT04849832).
  • Exercise: Indirect interaction; while no human trial has tested whether chlorophyllin blunts exercise-induced mitochondrial adaptation, systemic activation of NRF2, HO-1, and NQO1 (Zhang et al., 2008) suggests separating high-dose intake by 2–3 hours from training when maximizing reactive-oxygen-species signaling.
  • Stress management: None; no human studies indicate that chlorophyllin alters hypothalamic-pituitary-adrenal axis activity, salivary cortisol, or heart-rate variability, though outdoor mindfulness or sunlight exposure habits warrant broad-spectrum sun protection due to rare porphyrin-related skin photosensitivity (Rossi et al., 2015).

Monitoring Protocol & Defining Success

Before starting regular daily supplementation with oral sodium copper chlorophyllin, baseline laboratory testing typically includes serum copper, ceruloplasmin, and a hepatic panel to confirm normal hepatobiliary copper excretion and liver function, alongside a complete blood count (CBC, a standard blood panel measuring red cells, white cells, and platelets) or a 24-hour urinary TMA profile when specifically targeting leukocyte recovery or trimethylaminuria.

Ongoing monitoring is typically performed at 4 weeks for targeted hematologic or odor-control regimens, at 12 weeks for initial systemic safety verification, and every 6–12 months thereafter during chronic daily supplementation, while pausing oral intake 5–7 days prior to any guaiac-based stool occult blood screening.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum copper and ceruloplasmin Copper: 70–140 μg/dL; Ceruloplasmin: 20–40 mg/dL (standard reference range) Safety check: detects systemic copper accumulation that stops or changes use (Viera et al., 2025). Morning blood draw; rising copper above range indicates switching to copper-free sodium magnesium chlorophyllin.
Hepatic panel (ALT, AST, total bilirubin) ALT: 7–56 U/L; AST: 8–33 U/L; Bilirubin: 0.1–1.2 mg/dL (standard reference range) Safety check: detects cholestasis or liver injury that stops use (Egner et al., 2000). Fasting morning draw; liver enzymes ALT (alanine aminotransferase) and AST (aspartate aminotransferase) confirm intact clearance.
Complete blood count (CBC) with differential White blood cells: 4.5–11.0 × 10³/μL; Hemoglobin: 13.5–17.5 g/dL in men, 12.0–15.5 g/dL in women (standard reference range) Expected to change: tracks leukocyte recovery (Gao & Hu, 2005) or anemia response with iron-chelated forms (Zheng et al., 2025). Re-check at 4 weeks when used for hematologic support; includes MCV (mean corpuscular volume, average red blood cell size).
Urinary TMAO-to-total-TMA ratio >90% TMAO / (TMA + TMAO) (Yamazaki et al. target) Expected to change: confirms reduction of free urinary TMA in trimethylaminuria. 24-hour or post-choline urine collection; unaffected adult reference range is >95% (Yamazaki et al., 2004).
  • Digestive comfort: Absence of cramps or watery diarrhea alongside expected green stool.
  • Skin sun tolerance: Absence of hand or facial redness, fragility, or blistering.
  • Perceived odor: Reduced body, urinary, or ostomy odor when targeting deodorization.

Emerging Research

  • Phase 3 trial for radiation-induced gastrointestinal bleeding: NCT07837713 is a 200-patient double-blind phase 3 RCT (not yet recruiting; estimated completion September 2030) testing 500 mg/day oral sodium copper chlorophyllin versus placebo for 3 months. A positive result would establish clinical mucosal radioprotection; a null result would weaken systemic tissue-repair claims.
  • Phase 3 trial for late pelvic radiotherapy toxicity: NCT07164534 is a 316-patient phase 3 RCT (not yet recruiting; completion September 2030) evaluating 750 mg/day oral sodium copper chlorophyllin with standard care in cervical cancer survivors. A positive outcome would confirm late-toxicity mitigation; a null result would limit clinical radioprotective utility.
  • Ongoing phase 2 rectal and total-body irradiation trials: NCT05856305 (N = 76, active not recruiting, completion September 2027) and NCT07709195 (N = 17, recruiting, completion March 2027) test 750 mg/day chlorophyllin for acute radiation toxicity and mucositis (mucosal ulceration). Positive results would support radioprotection; null results would cap evidence at preclinical levels.
  • Trials past completion dates: Brain radionecrosis (radiation tissue death) phase 2 trial CHROME (NCT06016452; N = 118; Dasgupta et al., 2025) passed its November 2025 date (recruiting, no results posted), while single-arm cystitis trial CLARITY (NCT05348239; N = 24, completed March 2024) reported 70.8% response (Prakash et al., 2026).
  • Preclinical uroprotection, copper bioavailability, and tumor-promotion questions: Ramani et al., 2025 found an oral no-observed-adverse-effect level (NOAEL, highest dose without toxicity) >1,000 mg/kg and interleukin-22 (IL-22, epithelial-repair cytokine) restoration in mice, whereas Viera et al., 2025 confirmed hepatic copper-chlorin retention and Nelson, 1992 reported rat colon tumor promotion.

Conclusion

Chlorophyllin is a water-soluble metal-substituted derivative of plant chlorophyll that remains stable in the digestive tract and acts primarily by binding flat, ring-shaped dietary toxins in the gut before they can enter the bloodstream. For proactive, health-oriented adults, its strongest human evidence lies in reducing the absorption of foodborne mold toxins and harmful compounds from charred meat when administered orally with meals, alongside single-trial evidence for white blood cell recovery in people with low white blood cell counts and preliminary single-arm trial evidence for radiation-induced bladder bleeding. By contrast, controlled human trials for internal body and ostomy odor are conflicted, and large clinical trials for anemia apply only to a specialized iron-bound prescription derivative used in China rather than standard copper-bound supplements. Claims regarding lifespan extension, gut barrier repair, antiviral defense, and kidney stone prevention remain confined to laboratory and animal studies.

Oral sodium copper chlorophyllin is well tolerated in controlled human trials up to typical daily doses, with zero excess side effects over placebo, though higher intakes can loosen stools, tint stool and blood serum green, trigger false-positive chemical stool blood tests, and rarely provoke blistering skin sun sensitivity. Animal studies also raise unconfirmed questions regarding long-term copper retention and context-dependent colon tumor promotion. Furthermore, segments of the evidence base carry notable conflicts of interest: topical skin studies and open-label anemia surveillance were funded and co-authored by product manufacturers, and human immune-modulation and radioprotection studies come from investigators holding patents on the compound.

Top - Benefits - Risks - Protocol